癌癥藥物靶向ChIP PCR芯片 Cancer Drug Targets ChIP PCR Array

科技服務(wù) > 生物芯片實(shí)驗(yàn)服務(wù) > 癌癥藥物靶向ChIP PCR芯片 Cancer Drug Targets ChIP PCR Array

癌癥藥物靶向ChIP PCR芯片 Cancer Drug Targets ChIP PCR Array

Cancer Drug Targets ChIP PCR Array
運(yùn)費(fèi) ¥0.00
(庫存 9999 件)
地區(qū):上海
簡介:Cancer Drug Targets ChIP PCR Array
提供商:SAB
服務(wù)名稱:Cancer Drug Targets ChIP PCR Array
Human Cancer Drug Targets ChIP PCR Array

 
ProductSpeciesTechnologyCat. No.
Cancer Drug Targets EpiTect ChIP qPCR ArrayHumanHistone ModificationsGH-507A
Cancer Drug Targets EpiTect ChIP qPCR ArrayMouseHistone ModificationsGM-507A



The Human Cancer Drug Targets EpiTect Chip qPCR Array profiles the histone modification status or “histone code” of 84 actively sought targets for anticancer therapeutics and drug development. Histone modifications define chromatin structure, and some correlate closely with the transcriptional activity of associated genes. In vitro screening of therapeutics for a given cancer type increasingly depends on not only the activity, but also the expression and epigenetic status of oncogenes. For example, histone deacetylase (HDAC) inhibitors induce tumor suppressor gene expression, slowing growth and proliferation, but could also increase oncogene expression. The choice to add HDAC inhibitors to a drug regimen can depend on the histone codes of the two gene classes. Cancer cells with oncogenes in a heterochromatin state may respond better to HDAC inhibitor treatment because these genes would not be expressed or easily induced. Comprehensively understanding how oncogenes contribute to tumor growth and survival on the molecular level requires a determination of the epigenetic mechanisms regulating their expression. Using chromatin immunoprecipitation and this real-time PCR Array, you can easily and reliably analyze the histone modification patterns associated with a focused panel of important cancer-related genes.
The EpiTect Chip qPCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.




Apoptosis: BCL2, BIRC5. 
PI-3 Kinases & Phosphatases: FRAP1 (MTOR), PIK3C2A, PIK3C3, PIK3CA. 
Growth Factors & Receptors: EGFR, ERBB2, ERBB3, ERBB4, FIGF, FLT1, FLT4, IGF1, IGF1R, IGF2, KDR, KIT, PDGFRA, PDGFRB. 
Drug Metabolism: ABCC1, GSTP1, PTGS2, TXN, TXNRD1. 
G Protein Signaling: RHOA, RHOB. 
Hormone Receptors: ESR1, ESR2, PGR. 
Heat Shock Proteins: HSP90AA1, HSP90B1. 
Receptor Tyrosine Kinase Signaling: AKT1, AKT2, GRB2. 
Cathepsins: CTSB, CTSD, CTSL1, CTSS. 
Cell Cycle: CDC2, CDC25A, CDK2, CDK4, CDK5, CDK7, CDK8, CDK9, MDM2, MDM4, TERT. 
Topoisomerases, Type II: TOP2A, TOP2B. 
Transcription Factors: ATF2, HIF1A, IRF5, NFKB1, TP53. 
Protein Kinases: AURKA, AURKB, AURKC, PLK1, PLK2, PLK3, PLK4, PRKCA, PRKCB, PRKCD, PRKCE. 
RAS Signaling: HRAS, KRAS, NRAS. 
Histone Deacetylases: HDAC1, HDAC11, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8. 
Poly ADP-Ribose Polymerases: PARP1, PARP2, PARP4, TNKS. 
Structural Protein: NTN3.


姓名
電話號碼
電子郵箱
公司名稱
地址
留言*
 
驗(yàn)證碼
提交